Red Blood Cells News and Research

RSS

Aggressive treatment of anemia with ESAs may lower risk of death for dialysis patients: Study

Aggressive treatment of anemia with intravenous iron and drugs known as erythropoiesis-stimulating agents (ESAs) may lower the risk of death for dialysis patients with severe anemia - but also may increase the risk of death among patients with milder anemia, a new study led by a University of North Carolina at Chapel Hill epidemiologist suggests.

3 Mar 2010

Study reveals most consumers are unclear about dietary nutrients

When it comes to dietary nutrients, most consumers don't know the whole story. A recent study by the Innovation Center for U.S. Dairy revealed that the fact that milk delivers much more than calcium to the diet is new "news" to consumers.

2 Mar 2010

Habits of modern life may shorten life-span of the Millennium Generation

All parents dream of a better life for their children, but because of the habits of modern life, the Millennium Generation may be the first to suffer a shorter life-span.

1 Mar 2010

Researchers find gene regulator that plays key role in DS-AMKL

Between 5 and 10 percent of babies with Down syndrome develop a transient form of leukemia that usually resolves on its own. However, for reasons that haven't been clear, 20 to 30 percent of these babies progress to a more serious leukemia known as Down syndrome acute megakaryoblastic leukemia (DS-AMKL), which affects the blood progenitor cells that form red blood cells and platelets.

1 Mar 2010

Unexplained, sudden anemia: Brown recluse spider bite

As spring approaches and people return to outdoor activities, caution should be taken in areas of the country that are home to Loxosceles reclusa, also called the brown recluse spider. A new study from St. Jude Children's Research Hospital found that when patients present with sudden anemia, but the cause is elusive, the brown recluse spider should be part of the differential diagnosis, at least in parts of the nation where the spider is regularly found.

27 Feb 2010

Rare Disease Day 2010: Alexion Pharmaceuticals joins NORD and EURORDIS to raise awareness

Alexion Pharmaceuticals, Inc., has joined the National Organization for Rare Disorders (NORD) and the European Organization for Rare Diseases (EURORDIS) in supporting the goals of the third annual Rare Disease Day, February 28, 2010.

26 Feb 2010

Salmonella-infected mice help understand how symptoms of HLH develop

A new University of Colorado at Boulder study shows mice infected with the bacteria salmonella develop clinical signs consistent with a deadly and poorly understood human inflammatory disease, a finding that may lead to new therapies.

26 Feb 2010

Study to restrict hemoglobin-based oxygen carriers

study published in the March 2010 issue of the journal Anesthesiology gives researchers new insights in how to better understand and control a severe side effect of hemoglobin-based oxygen carriers (HBOCs), often referred to as "artificial blood."

23 Feb 2010

FDA grants Haemonetics clearance to collect two RBC on Cymbal system

On January 27, 2010 the FDA cleared the Haemonetics 510(k) for its expanded nomogram to collect two Red Blood Cells on the Cymbal® Automated Blood Collection System from female donors who are at least 150 pounds and are 63 inches in height. The Cymbal is a small, portable, battery operated instrument that automates blood collection from volunteer donors, improving process control and helping alleviate blood shortages.

23 Feb 2010

Two genetic alterations linked to benign enzyme condition keep hepatitis C patients anemia-free

Many people who undergo treatment for hepatitis C develop hemolytic anemia, a disorder that destroys red blood cells. In some cases, it is so severe they have to reduce their medication or stop therapy altogether. But now, scientists in Duke University's Institute for Genome Sciences & Policy have discovered two genetic alterations linked to a benign enzyme condition that keep some patients anemia-free.

21 Feb 2010

Mechanism by which Plasmodium replicates itself in human blood to spread disease identified

Malaria remains one of the most deadly infectious diseases. Yet, how Plasmodium, the malaria parasite, regulates its infectious cycle has remained an enigma despite decades of rigorous research.

19 Feb 2010

Blood transfusions based on single low hematocrit measurement questioned

A comparison study of nearly 1,900 patients published in Perfusion, a peer-reviewed academic journal, questions the long-standing practice of basing blood transfusion decisions on a single low hematocrit measurement result. In the study, titled Is it the Patient or the Physician who Cannot Tolerate Anemia?, researchers showed that a single measure of hematocrit is not a reliable indicator of transfusion need and that lower-than-normal hemoglobin levels have no adverse impact on patients.

19 Feb 2010

Six states to study sickle cell disease and thalassemias in national pilot project

Medical researchers are developing a new surveillance system to determine the number of patients diagnosed with a family of inherited blood disorders known as hemoglobinopathies, including sickle cell disease, thalassemias, and hemoglobin E disease.

19 Feb 2010

FDA approves risk management program on ESA's for treating anemia due to chemotherapy

The U.S. Food and Drug Administration today approved a risk management program to inform healthcare providers and their patients about the risks of a class of drugs called Erythropoiesis-Stimulating Agents (ESAs). For patients with cancer, the program is also designed to help ensure the appropriate administration of these drugs, which they receive to treat anemia that can occur as a result of chemotherapy.

17 Feb 2010

ERYtech Pharma announces collaborative research agreement with M. D. Anderson Cancer Center

ERYtech Pharma, a specialty pharma company located in France and in USA (Philadelphia), is pleased to announce a collaborative research agreement in the field of personalized medicine focusing on ERYtech’s flagship product, GRASPA®, which consists of red blood cell-encapsulated L-asparaginase (L-ASP).

15 Feb 2010

Proteins found in intestines can recognize and kill bacteria that have human blood type molecules

A set of proteins found in our intestines can recognize and kill bacteria that have human blood type molecules on their surfaces, scientists at Emory University School of Medicine have discovered.

15 Feb 2010

Therapeutic cell types obtained from iPS cells demonstrate abnormal expansion and early cellular aging

Advanced Cell Technology, Inc. or “ACT” reported that a range of therapeutic cell types obtained from induced pluripotent stem (iPS) cells exhibit abnormal expansion and early cellular aging. The research, which appears online (published-ahead-of- print) in the journal STEM CELLS by ACT and its collaborators at Stem International (SCRMI), Harvard Medical School, and the University of Illinois, compares a variety of replacement cell types derived from human iPS cells with their embryonic stem (ES) cell counterparts. The findings support the use of ACT’s single blastomere-derived human embryonic stem cell lines which do not display early aging.

12 Feb 2010

Therapeutic cell types obtained from iPS cells exhibit abnormal expansion and early cellular aging

Advanced Cell Technology, Inc. reported that a range of therapeutic cell types obtained from induced pluripotent stem (iPS) cells exhibit abnormal expansion and early cellular aging.

11 Feb 2010

Restricted fetal growth during first trimester linked to maternal high blood pressure and hematocrit levels

Factors such as maternal high blood pressure and high hematocrit levels (the proportion of blood that consists of red blood cells) are associated with a greater likelihood of restricted fetal growth during the first trimester, with restricted growth linked to an increased risk of preterm birth and low birth weight, according to a study in the February 10 issue of JAMA.

10 Feb 2010

Cerus enters into collaborative agreement with EFS for development of INTERCEPT Blood System

Cerus Corporation announced today that it has entered into a collaborative agreement with France's national transfusion service, the Etablissement Français du Sang (EFS), for the development of the company's INTERCEPT Blood System for red blood cells.

10 Feb 2010

Red Blood Cells News and Research

Aggressive treatment of anemia with ESAs may lower risk of death for dialysis patients: Study

Study reveals most consumers are unclear about dietary nutrients

Habits of modern life may shorten life-span of the Millennium Generation

Researchers find gene regulator that plays key role in DS-AMKL

Unexplained, sudden anemia: Brown recluse spider bite

Rare Disease Day 2010: Alexion Pharmaceuticals joins NORD and EURORDIS to raise awareness

Salmonella-infected mice help understand how symptoms of HLH develop

Study to restrict hemoglobin-based oxygen carriers

FDA grants Haemonetics clearance to collect two RBC on Cymbal system

Two genetic alterations linked to benign enzyme condition keep hepatitis C patients anemia-free

Mechanism by which Plasmodium replicates itself in human blood to spread disease identified

Blood transfusions based on single low hematocrit measurement questioned

Six states to study sickle cell disease and thalassemias in national pilot project

FDA approves risk management program on ESA's for treating anemia due to chemotherapy

ERYtech Pharma announces collaborative research agreement with M. D. Anderson Cancer Center

Proteins found in intestines can recognize and kill bacteria that have human blood type molecules

Therapeutic cell types obtained from iPS cells demonstrate abnormal expansion and early cellular aging

Therapeutic cell types obtained from iPS cells exhibit abnormal expansion and early cellular aging

Restricted fetal growth during first trimester linked to maternal high blood pressure and hematocrit levels

Cerus enters into collaborative agreement with EFS for development of INTERCEPT Blood System

Industry Focus eBook - Cell biology (5th edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News